Related references
Note: Only part of the references are listed.The role of upregulated miR-375 expression in breast cancer: An in vitro and in silico study
Wei Tang et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Circular RNA circKIF4A Sponges miR-375/1231 to Promote Bladder Cancer Progression by Upregulating NOTCH2 Expression
Ying-rui Shi et al.
FRONTIERS IN PHARMACOLOGY (2020)
Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression
Xueliang Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression
Yichong Ning et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
An integrative bioinformatics analysis identified miR-375 as a candidate key regulator of malignant breast cancer
Jiaxuan Liu et al.
JOURNAL OF APPLIED GENETICS (2019)
Up-regulated ADP-Ribosylation factor 3 promotes breast cancer cell proliferation through the participation of FOXO1
Danping Huang et al.
EXPERIMENTAL CELL RESEARCH (2019)
MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer
Mohammad Mijanur Rahman et al.
CELLS (2019)
Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF-κB and p53
Yan Zhang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer
Ying Ying Su et al.
JOURNAL OF OVARIAN RESEARCH (2019)
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Michael J. Duffy et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
Kathleen A. Cronin et al.
CANCER (2018)
Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development
Jacopo Sgrignani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Downregulation of Long Noncoding RNA HOTAIR and EZH2 Induces Apoptosis and Inhibits Proliferation, Invasion, and Migration of Human Breast Cancer Cells
Lu Han et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2018)
Emerging microRNAs in cancer diagnosis, progression, and immune surveillance
Amani M. Harrandah et al.
CANCER LETTERS (2018)
Magnesium in Breast Cancer: What Is Its Influence on the Progression of This Disease?
Priscyla Maria Vieira Mendes et al.
BIOLOGICAL TRACE ELEMENT RESEARCH (2018)
EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?
Ke-Sin Yan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling
Jing Tian et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
MiR-375: A prospective regulator in medullary thyoid cancer based on microarray data and bioinformatics analyses
Lin Shi et al.
PATHOLOGY RESEARCH AND PRACTICE (2017)
miRNA-223 suppresses FOX01 and functions as a potential tumor marker in breast cancer
Y-T. Wei et al.
CELLULAR AND MOLECULAR BIOLOGY (2017)
Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation Impact on Regulation of Notch Pathway
Hyunjoo Kwon et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Targeting EZH2 in cancer therapy
Makoto Yamagishi et al.
CURRENT OPINION IN ONCOLOGY (2017)
MicroRNA-9 promotes the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1
D. -Z. Liu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Naturally occurring anti-cancer agents targeting EZH2
Fahimeh Shahabipour et al.
CANCER LETTERS (2017)
FOXO transcription factors in cancer development and therapy
Alexandra Coomans de Brachene et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Constitutive activation of STAT3 in breast cancer cells: A review
Kasturi Banerjee et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Andreas C. Joerger et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 85 (2016)
DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers
Ching-Yu Yen et al.
CANCER LETTERS (2016)
Decreased expression of EZH2 reactivates RASSF2A by reversal of promoter methylation in breast cancer cells
Pan Yu et al.
CELL BIOLOGY INTERNATIONAL (2016)
Lateral Thinking: How Histone Modifications Regulate Gene Expression
Moyra Lawrence et al.
TRENDS IN GENETICS (2016)
DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression
Xianghong Ning et al.
CANCER LETTERS (2015)
Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information
Zorka Inic et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2014)
Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
Eunhee Kim et al.
CANCER CELL (2013)
Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils
Alexander H. Stegh
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu et al.
SCIENCE (2012)
Share Paper
